Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Feline calicivirus vaccine

a vaccine and feline calicivirus technology, applied in the field of new vaccines for feline calicivirus, can solve the problems of not efficiently neutralizing all current field isolates, persistent infection, and inability to protect cats

Active Publication Date: 2020-10-29
INTERVET INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides vectors that encode one or more feline calicivirus (FCV) antigens. These vectors can be used in immunogenic compositions and vaccines to protect against FCV. The vectors are based on alphavirus RNA replicon particles, which can be a Venezuelan Equine Encephalitis (VEE) alphavirus RNA replicon particle or a Sindbis (SIN) alphavirus RNA replicon particle. The immunogenic compositions and vaccines can also contain other antigens, such as non-FCV antigens or antigenic fragments thereof. The invention provides methods for making and using the immunogenic compositions and vaccines.

Problems solved by technology

Cats infected with FCV may become persistently infected, and may shed infectious virus for long periods of time.
Although, long characterized as belonging to a single serotype, FCV isolates are antigenically highly variable, and antibodies from cats vaccinated with older vaccine strains of FCV, such as FCV F9, do not efficiently neutralize all current field isolates.
These “virulent systemic” (VS-FCV) isolates are responsible for localized outbreaks, and current vaccines also do not appear to protect cats from disease caused by these strains.
This has led to concern that cats vaccinated with current vaccine strains are not fully protected from disease caused by such “antigenically heterologous” FCV strains, and that these heterologous strains may be responsible for outbreaks of disease, even in vaccinated cats.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Incorporation of the Coding Sequences for FCV Capsid Proteins into the Alphavirus RNA Replicon Particles

Introduction

[0072]RNA viruses have been used as vector-vehicles for introducing vaccine antigens, which have been genetically engineered into their genomes. However, their use to date has been limited primarily to incorporating viral antigens into the RNA virus and then introducing the virus into a recipient host. The result is the induction of protective antibodies against the incorporated viral antigens. Alphavirus RNA replicon particles have been used to encode pathogenic antigens. Such alphavirus replicon platforms have been developed from several different alphaviruses, including Venezuelan equine encephalitis virus (VEE) [Pushko et al., Virology 239:389-401 (1997)], Sindbis (SIN) [Bredenbeek et al., Journal of Virology 67:6439-6446 (1993) the contents of which are hereby incorporated herein in their entireties], and Semliki Forest virus (SFV) [Liljestrom and Garoff, Biotechn...

example 2

Evaluation of Efficacy and Safety of a Dual Construct FCV Vaccine in Cats

[0077]A dual-construct vaccine comprising a propagation defective RNA particle (RP) encoding the capsid proteins from two different strains of FCV, a virulent systemic strain (VS-FCV) and a classical vaccine strain (FCV F9-Like) along with the capsid protein and glycoproteins of the avirulent TC-83 strain of Venezuelan Equine Encephalitis Virus (VEE) was formulated in 5% sucrose and stored frozen. This dual-construct vaccine was used to evaluate the effectiveness against challenge by two FCV strains, as shown in Table 1 below. Two groups of 10 cats each were vaccinated with the dual-construct FCV vaccine in a prime / boost regimen at 13-14 weeks of age and then 21 days later. Two groups of control cats were vaccinated by the same regimen with a placebo vaccine consisting of cell culture media (Minimal Essential Media with Earle's salts, EMEM).

TABLE 1VACCINATION PROTOCOLTreatmentNo. ofTestVaccineChallengeGroupAnim...

example 3

Evaluation of Interference with Administration of Two Different RNA Particle Vaccines

[0082]The study was conducted to evaluate multiple aspects of the alphavirus RNA replicon particle FCV vaccine including serological response, efficacy against challenge, and interference. A RP-FCV construct vaccine encoding the capsid protein of a classical FCV vaccine strain (F9) was formulated in stabilizer consisting of gelatin, NZ-amine, and sucrose and lyophilized. Two groups of five cats were vaccinated with the RP-FCV vaccine at 17 weeks of age. Twenty-one days later, cats in Group 1 were administered a booster dose of the RP-FCV vaccine only, cats in Group 2 were administered a booster dose of the RP-FCV vaccine and administered a dose of an RP-Rabies vaccine at the same time as shown in Table 3 below. The RP-Rabies virus vaccine is a construct encoding the rabies virus glycoprotein (G) in the same TC-83 VEE alphavirus platform.

TABLE 3VACCINATION PROTOCOLTreatmentTest Product -InitialTest P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
immunogenic compositionaaaaaaaaaa
timeaaaaaaaaaa
immunogenic compositionsaaaaaaaaaa
Login to View More

Abstract

The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. § 119(e) of provisional application U.S. Ser. No. 62 / 596,508 filed Dec. 8, 2017, U.S. Ser. No. 62 / 582,050 filed Nov. 6, 2017, U.S. Ser. No. 62 / 581,955 filed Nov. 6, 2017, and U.S. Ser. No. 62 / 599,401 filed Dec. 15, 2017, the contents of which are hereby incorporated by reference in their entireties.FIELD OF THE INVENTION[0002]The present invention relates to new vaccines for feline calicivirus. Methods of making and using the vaccines alone or in combination with other protective agents are also provided.BACKGROUND[0003]Feline calicivirus (FCV) is usually associated with upper respiratory disease in cats. FCV together with feline herpesvirus are thought to be responsible for approximately 80% of all feline respiratory disease. The most common characteristic and clinical signs of FCV infection is the development of vesicles (ulcers) on the tongue and oral mucosa. These vesicles begin as smal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/12C12N7/00
CPCA61K39/12C12N7/00C12N2770/36143A61K2039/552C12N2770/16034C12N2710/16734C12N2750/14034A61K39/118A61K2039/5256A61K2039/5258C12N2760/20134A61K39/295A61K2039/70A61K2039/53
Inventor TARPEY, IAN
Owner INTERVET INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com